Balancing Effortful and Errorless Learning in Naming Treatment for Aphasia
Launched by UNIVERSITY OF PITTSBURGH · Dec 7, 2022
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying new ways to help people with aphasia, a language disorder often caused by stroke, improve their ability to find and use words in everyday situations. Many people with aphasia struggle with a specific type of word-finding difficulty called anomia, which can make communication frustrating. The researchers are exploring treatment approaches that not only help participants remember words better over the long term but also encourage them to use these words in their daily lives.
To be eligible for this study, participants must be at least 65 years old and have had aphasia for more than six months following a stroke that affected the left side of the brain. They should also have some difficulty with language, as shown in a specific test. However, those with certain other neurological issues, serious language understanding problems, or significant mental health challenges won't be able to participate. If you join, you can expect to engage in activities designed to improve your naming abilities, with support from the research team throughout the process.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Existing diagnosis of chronic (\>6 months) aphasia subsequent to left hemisphere stroke.
- • Impaired performance on 2/8 sections of the Comprehensive Aphasia Test.
- Exclusion Criteria:
- • History of other acquired or progressive neurological disease.
- • Significant language comprehension impairments (per performance on the CAT - individuals will be excluded if their spoken language comprehension mean modality T- score on the CAT falls below 40).
- • Unmanaged drug / alcohol dependence.
- • Severe diagnosed mood or behavioral disorders that require specialize mental health interventions.
About University Of Pittsburgh
The University of Pittsburgh is a leading research institution known for its commitment to advancing medical science and improving patient care through innovative clinical trials. With a robust infrastructure for research and a multidisciplinary approach, the university fosters collaboration among experts in various fields, facilitating the development of novel therapies and interventions. Its clinical trial programs emphasize ethical standards, patient safety, and the integration of cutting-edge technology, making the University of Pittsburgh a pivotal contributor to the landscape of clinical research and a trusted partner in the pursuit of health advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pittsburgh, Pennsylvania, United States
Patients applied
Trial Officials
William Evans, PhD
Principal Investigator
University of Pittsburgh
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials